Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer (Q68178641)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

0 references

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

15 October 2022

author name string

C. Rangel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1615614

15 October 2022

H. Matzkin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1615614

15 October 2022

M. S. Soloway

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1615614

15 October 2022

language of work or name

English

0 references

publication date

1 June 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

22 September 2019

https://api.elsevier.com/content/article/PII:009042959290023P?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

https://api.elsevier.com/content/article/PII:009042959290023P?httpAccept=text/plain

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

15 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

577-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

Proceedings: The natural history of prostatic cancer

22 September 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report

15 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial

15 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: Prognostic factors and response

15 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer. Scottish Urological Oncology Group.

15 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

15 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

15 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate

15 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

15 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity

15 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

15 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

Low-dose Doxorubicin in the Management of Advanced Carcinoma of the Prostate

15 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0090-4295(92)90023-P

15 October 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1615614%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference